ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 26, 2021 19:41 JST
Source:
Tianda Pharmaceuticals Limited
天大藥業2021年中期業績
業務顯著增長
繼續加強創新研發、加大業務拓展力度
香港, Nov 26, 2021 - (ACN Newswire) - 天大藥業有限公司(天大藥業或本集團 ,股份代號 :0455.HK) 欣然宣佈截至2021年9月30日止六個月(報告期)的中期業績。報告期內,本集團三個業務板塊均錄得顯著增長,收入2億3,650萬港元,同比增長26.2%。本集團財務狀況穩健,於2021年9月30日,淨資產7億7,700萬港元,銀行結餘及現金2億220萬港元,加上未動用銀行貸款額度7,780萬港元,本集團具充足財務資源支持業務穩步發展。
中醫藥業務收入5,800萬港元,同比增長64.2%。順應國家對中醫藥產業的政策支持,本集團經過逾五年的努力已形成中醫藥全產業鏈佈局,涵蓋中藥材貿易、中藥飲片生產、中醫藥研發、中藥全產品線及國內外購銷。藥物和醫療科技業務收入1億7,490萬港元,同比增長16.6%。主要產品心腦血管用藥托平®纈沙坦膠囊在全國同類產品中銷量第一,正抓住在國家第三批集中帶量採購第一順位中標的機會,放量增長。位於珠海金灣的新研發及製藥基地將於明年1月投產,銳意打造成為一個高標準、高質量、高效能的醫藥健康產業基地。醫療和保健服務收入360萬港元,同比增長79.5%。報告期內,首次採用股權投資合作模式與著名中醫專家共同投資開設天大館, 該合作模式將成為快速拓展天大館的重要手段。同時,本集團加快構建中醫雲端科技平臺「雲上天大館」,提供線上智能診症、大健康電商等服務,與天大館實體館互相助力,致力發展「天大館」成為中醫館第一品牌。
本集團繼續加強創新和研發,在經典名方開發、心腦血管用藥、兒科用藥、糖尿病用藥等方面均有序推進。同時,加大業務拓展(BD)力度,與研發有機聯動,通過外部引進、自主研發、合作研發等方式,提高管線內研發項目的品質和數量,進一步豐富產品線,並在全球範圍內尋找前沿技術和產品機會,助力公司整體業務發展。
國家在「第十四個五年規劃和2035年遠景目標綱要」中提出推動中醫藥傳承創新,堅持中西醫並重和優勢互補,大力發展中醫藥事業,為本集團業務發展提供良好的政策紅利。本集團將貫徹實施「三個發展」的戰略,深度佈局三大業務板塊,積極審視併購機會,加快業務增長和規模擴大步伐,致力發展成為立足中國,輻射全球的領先醫藥企業,為守護人類健康做出更大貢獻。
有關天大藥業有限公司
天大藥業有限公司(香港聯交所上市公司,股份代號0455)以發展中醫藥產業為基礎,發展創新藥物和醫療科技,發展優質醫療和保健服務,致力發展成為立足中國,輻射全球的領先醫藥企業。
新聞查詢
天大藥業有限公司
投資者關係部
電話:+852 2545 3313 電郵:
ir@tianda.com
Source: Tianda Pharmaceuticals Limited
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>
Related Release
Tianda Pharma Announces 2022/23 Interim Results
November 25 2022 23:54 JST
Tianda Pharmaceuticals Annual Results 2022
June 30 2022 11:40 JST
Tianda Pharma Interim Results 2021
November 26 2021 18:40 JST
The third TDMall in the world opened in Sydney, Australia
March 16 2021 19:52 JST
Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout
March 04 2021 19:43 JST
Tianda Pharmaceuticals acquired and established a long-term relationship of Cooperation with Yeung & Young Medicare and Qi's Living
October 06 2020 11:00 JST
HK Main-Board Listed Tianda Pharmaceuticals (00455.HK) Promising Outlook for Growth
July 10 2020 15:26 JST
More Press release >>